![Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial - Annals of Oncology Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial - Annals of Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/4a3b1249-6039-43e2-b043-6344633ae667/gr1_lrg.jpg)
Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial - Annals of Oncology
![The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - ScienceDirect The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0305737220300608-gr4.jpg)
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - ScienceDirect
![Frontiers | Beyond Conventional: The New Horizon of Targeted Therapy for the Treatment of Advanced Non Small Cell Lung Cancer | Oncology Frontiers | Beyond Conventional: The New Horizon of Targeted Therapy for the Treatment of Advanced Non Small Cell Lung Cancer | Oncology](https://www.frontiersin.org/files/Articles/632256/fonc-11-632256-HTML-r1/image_m/fonc-11-632256-g001.jpg)
Frontiers | Beyond Conventional: The New Horizon of Targeted Therapy for the Treatment of Advanced Non Small Cell Lung Cancer | Oncology
![Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer | Journal of Hematology & Oncology | Full Text Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer | Journal of Hematology & Oncology | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13045-021-01138-7/MediaObjects/13045_2021_1138_Fig1_HTML.png)
Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer | Journal of Hematology & Oncology | Full Text
![Timeline for crizotinib development. Abbreviations: ALK1, ALK-positive;... | Download Scientific Diagram Timeline for crizotinib development. Abbreviations: ALK1, ALK-positive;... | Download Scientific Diagram](https://www.researchgate.net/profile/Huanyu-Chen-2/publication/265213102/figure/fig2/AS:667811546406935@1536230088909/Timeline-for-crizotinib-development-Abbreviations-ALK1-ALK-positive-ASCO-American.png)
Timeline for crizotinib development. Abbreviations: ALK1, ALK-positive;... | Download Scientific Diagram
![The emerging treatment landscape of targeted therapy in non-small-cell lung cancer | Signal Transduction and Targeted Therapy The emerging treatment landscape of targeted therapy in non-small-cell lung cancer | Signal Transduction and Targeted Therapy](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41392-019-0099-9/MediaObjects/41392_2019_99_Fig1_HTML.png)
The emerging treatment landscape of targeted therapy in non-small-cell lung cancer | Signal Transduction and Targeted Therapy
![The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable - ScienceDirect The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S016950021630527X-gr2.jpg)
The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable - ScienceDirect
![Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration | Nature Medicine Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration | Nature Medicine](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41591-019-0716-8/MediaObjects/41591_2019_716_Fig1_HTML.png)
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration | Nature Medicine
![MET Exon 14 Skipping Alterations in NSCLC: Current Understanding and Therapeutic Advances - touchONCOLOGY MET Exon 14 Skipping Alterations in NSCLC: Current Understanding and Therapeutic Advances - touchONCOLOGY](https://touchoncology.com/wp-content/uploads/sites/2/2020/12/Fig-2-1.jpg)
MET Exon 14 Skipping Alterations in NSCLC: Current Understanding and Therapeutic Advances - touchONCOLOGY
![The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - ScienceDirect The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0305737220300608-gr1.jpg)
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - ScienceDirect
![i>MET</i> Exon 14 Skipping Mutations in Non-Small-Cell Lung Cancer: An Overview of Biology, Clinical Outcomes, and Testing Considerations. - Abstract - Europe PMC i>MET</i> Exon 14 Skipping Mutations in Non-Small-Cell Lung Cancer: An Overview of Biology, Clinical Outcomes, and Testing Considerations. - Abstract - Europe PMC](https://europepmc.org/articles/PMC8140815/bin/po-5-po.20.00516-g001.jpg)
i>MET</i> Exon 14 Skipping Mutations in Non-Small-Cell Lung Cancer: An Overview of Biology, Clinical Outcomes, and Testing Considerations. - Abstract - Europe PMC
![Introduction - Targeting METex14 NSCLC - Text Module - MET Inhibition in NSCLC - Oncology - Clinical Care Options Introduction - Targeting METex14 NSCLC - Text Module - MET Inhibition in NSCLC - Oncology - Clinical Care Options](https://www.clinicaloptions.com/-/media/oncology/programs/nsclc-metex14/module-thumbs/cco-metex14-asco-cf_thumb5.png?rev=56ffef7061e0418789a91bd59b7bb14c)
Introduction - Targeting METex14 NSCLC - Text Module - MET Inhibition in NSCLC - Oncology - Clinical Care Options
![MET Exon 14 Skipping Alterations in NSCLC: Current Understanding and Therapeutic Advances - touchONCOLOGY MET Exon 14 Skipping Alterations in NSCLC: Current Understanding and Therapeutic Advances - touchONCOLOGY](https://touchoncology.com/wp-content/uploads/sites/2/2020/12/Fig-1-1.jpg)
MET Exon 14 Skipping Alterations in NSCLC: Current Understanding and Therapeutic Advances - touchONCOLOGY
![Introduction - Targeting METex14 NSCLC - Text Module - MET Inhibition in NSCLC - Oncology - Clinical Care Options Introduction - Targeting METex14 NSCLC - Text Module - MET Inhibition in NSCLC - Oncology - Clinical Care Options](https://www.clinicaloptions.com/-/media/oncology/programs/nsclc-metex14/module-thumbs/cco-metex14-asco-cf_thumb11.png?rev=2592d5f249184e3c836951881e62602a)